There have been several updates to the Limited Coverage Drug Program for the treatment of Parkinson's disease.
Limited coverage drugs are not generally considered to be first-line therapies or there are more cost-effective alternatives.
To be eligible for coverage of these drugs, the patient must meet criteria pre-defined by PharmaCare. Actual coverage depends on rules of the patient's PharmaCare plan, including any annual deductible requirement.
Effective November 13, 2018, rotigotine has been listed for access through special authority. As well, the criteria for both pramipexole and ropinorole have been updated.
For more information, please visit the criteria pages for each drug under the Limited Coverage Drug Program: